The GAPVAC-101 trial reported 50% APVAC1-induced and 84.7% APVAC2-induced immunogenicity with CD8+ and CD4+ T cell responses in 92% (12/13) and 80% (8/10) immune responders, respectively...Dexamethasone use had limited immunogenicity in a trial by Keskin et al (6/8)...Actively personalized vaccines aimed at unmutated peptides and neoantigens for patients with GBM are safe and highly immunogenic, particularly when administered in combination. Larger studies are warranted to investigate the role.
3 years ago
Clinical • Review • Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)